LEN vs TXMD · rev $34.19B vs rev $1.8M
LEN (LEN) versus TherapeuticsMD Inc (TXMD) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
TherapeuticsMD Inc (TXMD) is a drug manufacturers - specialty & generic company listed on US.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
Latest reported TXMD revenue for 2024-12-31 was $1.8M. Net income was -$2.2M. Revenue was up 35.3% from 2023-12-31 to 2024-12-31. TXMD currently screens at market cap $13.7M.
LEN currently screens at market cap $0. TXMD currently screens at market cap $13.7M.
Not investment advice. Open the LEN and TXMD stock pages for the full models.
Not investment advice.